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Serum Lipid Levels and Risk Of 
Hand Osteoarthritis: The Chingford 
Prospective Cohort Study
M. Garcia-Gil1,2, C. Reyes3,4, R. Ramos1,2,5, M. T. Sanchez-Santos6,7, D. Prieto-Alhambra3,4,6,8, 
T. D. Spector9, D. J. Hart9 & N. K. Arden  6,7,8
The development of hand osteoarthritis (HOA) could be linked to hyperlipidaemia. No longitudinal 
studies have addressed the relationship between serum lipid profile and HOA. The study aim was 
to determine the association between serum lipid profile and the incidence of radiographic hand 
osteoarthritis (RHOA). All women in a prospective population-based cohort from the Chingford study 
with available baseline lipid measurements and without RHOA on a baseline were included. Study 
outcome was the incidence of RHOA in year 11 of follow-up. Serum lipid profile variables were analysed 
as continuous variables and categorised into quartiles. The association between serum lipid profile and 
RHOA was modeled using multivariable logistic regression. Overall RHOA incidence was 51.6% (45.7–
57.4%). An inverse association between HDL cholesterol levels and the incidence of RHOA was observed 
by quartile: OR of 0.36 [95%CI 0.17–0.75], 0.52 [95%CI 0.26–1.06], and 0.48 [95%CI 0.22–1.03]. 
Triglycerides levels showed a significant trend. No relationship was found with total or LDL cholesterol. 
Higher levels of HDL cholesterol appear to protect against RHOA after 11 years of follow-up. More 
research is needed to elucidate HOA risk factors, the mechanisms related to the lipid pathway, and the 
effects of lipid-lowering agents on reducing the incidence of OA.
Osteoarthritis (OA) is a prevalent and disabling disease that contributes to increased co-morbidity and is more 
common in the elderly. The association between OA and cardiovascular disease (CVD) has attracted a large 
portion of research attention in recent years. These two health conditions frequently co-exist and the disease 
burden is only partly explained by age. Cardiovascular mortality is increased in individuals with OA1 and a high 
prevalence of CVD risk factors has been described in these individuals2–4, suggesting the existence of common 
pathogenic mechanisms. However, the causal association is not clear5.
Substantial evidence has also linked obesity and metabolic syndrome with OA6–12. In addition, recent exper-
imental and epidemiological studies suggest that the biological mechanisms involved in the development of OA 
could be linked to atherosclerosis and the lipid metabolic pathway13–16, particularly in non-weight-bearing joints 
like those of the hand17–19. The estimated prevalence of radiological hand osteoarthritis (RHOA) in the elderly 
is about 80%, and there is evidence of sex-related and genetic predisposition. Risk factors such as age, manual 
labour, repetitive movement of the hand, overweight, smoking, and age at menopause have been associated with 
RHOA20. However, no longitudinal studies have addressed the relationship between serum lipid profile and OA 
in non-weight-bearing joints.
Our study aimed to determine if serum lipid profile is associated with incident radiographic hand osteoar-
thritis (RHOA).
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Methods
Setting and participants. Participants were selected from the Chingford Women’s Study, a prospective, 
population-based cohort study that has been described in detail elsewhere21. Briefly, all women aged 45–64 years 
registered at a large general practice in Chingford, North London (UK), were contacted in 1988–1989 and asked 
to participate in a population-based study to evaluate risk factors for osteoporosis and OA. Of 1,353 women con-
tacted, 1,003 (78%) attended the baseline visit (Y1) and signed their informed consent to participate. All women 
without RHOA on a baseline hand X-ray were included. The study participants were similar to women in the UK 
general population in terms of weight, height, and body mass index (BMI)12.
Radiographic assessment of RHOA. A standard hand X-ray was carried out at Y1 and at Y11. At both 
timepoints, RHOA was scored according to the Kellgren and Lawrence (K & L) scale by a single trained observer 
(DJH), blinded to clinical details, using the figures and legends of the original atlas22. The protocols used for radi-
ographic classification and reproducibility have been previously reported23, 24. Briefly, observer kappa statistics 
for both the interphalangeal and carpo-metacarpal joint groups ranged from 0.7 to 1.0 without any significant 
differences in the reproducibility of the clinical and radiological measures. RHOA was considered to be present if 
the women had either proximal or distal interphalangeal joint OA (PIP and DIP, respectively) with a K & L score 
≥2 in two or more joints. The outcome was defined as having RHOA at Y11.
Serum lipid profile measurements. The exposure of interest was the fasting serum lipid profile at the 
baseline visit (Y1): Total cholesterol (TC), HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c) and triglycerides 
(TG) at baseline, following a previously published protocol11.
Final study 
population N = 277
Lost to follow-up 
(N = 306)
No serum lipid 
profile (N = 107)
N (%) N (%) N (%)
Age* 50.4 (4.8) 55.4 (6.1) 54.4 (4.7)
Any current education 81 (29.2) 141 (46.2) 41 (38.2)
Blood pressure 
medication 30 (10.8) 50 (16.3) 18 (16.8)
Diabetes medication 6 (2.1) 1 (0.3) —
Statins 8 (2.9) 5 (14.7) 7 (6.5)
Previous CVD 3 (1.0) 18 (5.9) 1 (0.9)
Menopause 163 (58.8) 247 (80.9) 88 (82.2)
Age at menopause* 45.9 (5.7) 47.6 (5.1) 47.2 (4.9)
Previous HRT 70 (25.2) 79 (25.8) 27 (25.2)
Smoking
 Ex-smoker 62 (22.3) 75 (24.5) 29 (27.1)
 Current 69 (24.9) 79 (25.8) 18 (16.8)
Extent of activity in job
 Sedentary 11 (4.0) 12 (4.1) 13 (54.8)
 Half sedentary + half 
active 211 (77.0) 236 (78.9) 37 (25.6)
 Predominantly manual 52 (19.0) 51 (17.0) 10 (9.6)
Sport
 None 183 (66.7) 220 (73.3) 57 (54.8)
 Light 38 (13.8) 39 (13.0) 20 (19.2)
 Moderate 35 (12.7) 16 (5.3) 17 (16.3)
 Intensive 18 (6.8) 25 (8.4) 10 (9.6)
 Obesity 24 (8.6) 58 (18.9) 15 (14.0)
 BMI* 24.8 (3.9) 26.1 (5.0) 25.5 (3.8)
Blood pressure (mmHg)*
 Systolic 122.4 (19.9) 130.3 (20.1) 128.8 (15.2)
 Diastolic 76.4 (11.2) 79.6 (11.5) 78.1 (9.2)
 Glucose mmol/L* 4.9 (0.1) 5.0 (0.8) —
 TG mmol/L* 1.1 (0.6) 1.2 (0.6) —
 TC mmol/L* 6.3 (1.3) 6.7 (1.3) —
 HDL-c mmol/L* 1.7 (0.4) 1.7 (0.4) —
 LDL-c mmol/L* 4.1 (1.1) 4.4 (1.2) —
Table 1. Baseline characteristics of the study population. Numbers are percentages unless otherwise stated. 
*Mean (standard deviation). CVD: cardiovascular disease; HRT: hormone replacement therapy. TG: 
triglycerides, TC: total cholesterol, HDL-c: high-density lipoprotein cholesterol, LDL-c: low-density lipoprotein 
cholesterol.
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Study variables and covariates. The following variables were characterized at baseline and included in 
the analysis: age, any current medication, diabetes medication, statins use, hormone replacement therapy (HRT), 
previous CVD, menopause, age at menopause, smoking, extent of job-related activity, body mass index (BMI), 
and systolic and diastolic blood pressure. Age, age at menopause, BMI, and systolic and diastolic blood pressure 
were treated as continuous variables. Smoking was classified as never smoked, ex-smoker, or currently smoking. 
Extent of activity on the job was classified as sedentary, half sedentary and half active, and predominantly manual, 
obesity as BMI ≥ 30, and daily sports activity as none, light (1 hour walking, bowling, golf, badminton, cycling, 
or swimming), moderate (2 hours of light sport or 1 hour keep-fit or aerobics activity) and intensive (>1 hour 
keep-fit or aerobics, squash).
Statistical analysis. Continuous variables were described as mean and standard deviation and categori-
cal variables as percentages. Differences between groups were based on the t-test or chi-square, as appropriate. 
Cumulative incidence and 95% confidence intervals (CI) for RHOA were also calculated for a 11-year follow-up 
period.
Logistic regression models were used to evaluate the association between lipid serum profile and incidence of 
RHOA at Y11. Lipid serum profile was considered as both a continuous and categorical set of variables to evaluate 
the effect of a potential dose-response relationship with RHOA. Three different models were built to explore this 
association: Model 1 was non-adjusted, Model 2 was age-adjusted, and Model 3 added the potential confounders 
that were epidemiologically relevant or statistically significant in the bivariate analysis. Log-rank test was used to 
contrast the dose-response relationship within serum lipid profile categories.
We used STATA software (version 12) for all the analysis, with two-sided tests. P-values < 0.05 were consid-
ered statistically significant.
The study was approved by the Outer North East London Research Ethic Committee and conducted accord-
ing the rules of good research practices of the Declaration of Helsinki. Each study participant provided written 
informed consent before participating.
Results
Of the 1,003 women participating at baseline, 306 were lost to follow-up (30%) and 697 completed the year 11 
follow-up, of which 313 (45%) had RHOA at baseline and 107 (15%) had no baseline lipid serum profile measure-
ments data. The final sample available for analysis was 277 (40%) participants. Baseline participant characteristics 
are reported in Table 1 and the study flowchart is shown in Fig. 1.
The final study population was younger and had a healthier cardiovascular profile than women lost to 
follow-up and those without serum lipid profile measurements, although the percentages of smokers and of 
women with manual-labour jobs were higher in the final study population, compared to those without lipid 
profile measurements.
The mean age of the final study population was 50.4 (SD: 4.8) years and BMI was 24.8 (SD: 3.9). About 59% 
were post-menopausal, 19% had a predominantly manual-labour job, and just 8.6% were classified as obese.
Figure 1. Flowchart of the study population.
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Association between lipid serum profile and RHOA. Overall cumulative RHOA incidence was 51.6% 
[45.7–57.4%]. Compared to those without RHOA at Y11, incident RHOA women were older (51.1 [SD: 5.0]), 
more likely to take blood pressure medication (13.95% vs 7.9%) and had higher mean levels of triglycerides at 
baseline [1.0 (0.6) vs (1.2 (0.7)], with no other significant differences (Table 2).
Crude data and age- and fully adjusted logistic regression modelling results are detailed in Table 3. No sig-
nificant association was found between continuous HDL-c and incident RHOA. HDL-c levels were inversely 
associated with the incidence of RHOA, with crude OR 0.32 [95%CI 0.16–0.66], 0.50 [95%CI 0.25–0.99], and 0.50 
[95%CI 0.23–1.04] for the 2nd, 3rd, and 4th quartiles compared to the 1st quartile (reference group); this association 
remained unchanged and showed a significant trend after adjusting for all pre-specified confounders (OR: 0.36 
[95%CI 0.17–0.75], 0.52 [95%CI 0.26–1.06], and 0.48 [95%CI 0.22–1.03], respectively).
Conversely, TG levels were directly associated with RHOA incidence in the unadjusted continuous logistic 
model but the association was not significant after adjustment for age. Test for linear trend was significant in the 
fully adjusted categorical logistic model. No associations were found with TC and LDL-c levels and RHOA over 
11 years of follow-up.
Discussion
In this population-based cohort study, higher levels of HDL-c were found to be associated with a lower inci-
dence of RHOA over 11 years of follow-up. Conversely, the effect size observed in each TG category showed an 
increased, but not significant, risk for HOA. However, TG levels seem to confer a higher risk of RHOA according 
to the trend in test results.
Our results disagree with those of a previous cross-sectional study in the Chingford cohort11, in which the 
authors found an association between radiological knee OA and moderately elevated TC but no association 
No RHOA 
n = 134
RHOA 
n = 143 P-value
Age* 49.6 (4.6) 51.1 (5.0) 0.009
Any current medication 36 (26.8) 45 (31.4) 0.40
Blood pressure medication 10 (7.4) 20 (13.9) 0.08
Diabetes medication 4 (2.9) 2 (1.4) 0.36
Statins 4 (2.9) 4 (2.8) 0.92
Previous CVD 2 (1.5) 1 (0.7) 0.52
Menopause 73 (54.4) 90 (62.9) 0.15
Age at menopause* 45.4 (5.8) 46.3 (5.60) 0.31
Previous HRT 29 (21.6) 41 (28.6) 0.18
Smoking
 Ex-smoker 24 (1.9) 38 (26.5)
0.21
 Current 34 (25.3) 35 (24.4)
Extent of activity in job
0.76
 Sedentary 7 (5.2) 4 (2.8)
 Half sedentary + half 
active 102 (76.7) 109 (77.3)
 Predominantly manual 24 (18.1) 28 (19.8)
Sports activity
0.28
 None 93 (69.9) 90 (63.8)
 Light 15 (11.2) 23 (16.3)
 Moderate 19 (14.2) 16 (11.3)
 Intensive 6 (4.5) 12 (8.5)
 Obesity 14 (10.4) 10 (6.9) 0.30
 BMI* 24.70 (4.1) 24.95 (3.7) 0.60
Blood pressure (mmHg)
 Systolic 122.0 (20.9) 122.7 (19.9) 0.79
 Diastolic 75.8 (11.3) 76.9 (11.1) 0.42
 Glucose mmol/L* 4.9 (0.9) 4.9 (0.8) 0.99
 TG mmol/L* 1.0 (0.6) 1.2 (0.7) 0.01
 TC mmol/L* 6.2 (1.2) 6.4 (1.3) 0.06
 HDL-c mmol/L* 1.7 (0.4) 1.7 (0.4) 0.43
 LDL-c mmol/L* 3.9 (1.1) 4.1 (1.2) 0.14
Table 2. Baseline characteristics of study population according to incident radiographic hand osteoarthritis 
(RHOA) at 11 years of follow-up. Numbers are percentages unless otherwise stated. *Mean (standard deviation) 
CVD: cardiovascular disease; HRT: hormone replacement therapy, BMI: body mass index; TG: triglycerides, 
TC: total cholesterol, HDL-c: high-density lipoprotein cholesterol, LDL-c: low-density lipoprotein cholesterol.
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between knee OA and higher levels of LDL-c, TG, or HDL-c. In a subanalysis in women with both hand and knee 
OA, no association was found between any of the components of the serum profile and OA. Our study, based on 
the same cohort, showed a significant association and a trend in HDL-c because of differences in study design 
and baseline characteristics of the women included. In the previous study, women with previous RHOA were 
included, and they were older and had a worse CVD profile, compared to our study participants.
Other studies have shown contradictory results on the relationships between TC, TG, LDL-C and OA inci-
dence. The Rotterdam study8, which aimed to analyse the connection between HOA and overweight, detected 
no association between HOA and TC/HDL-c ratio, whereas our findings that HDL-c levels and TG levels were 
associated with HOA are consistent with other studies such as those of Davis-Tuck, who found higher levels of 
TC and TG associated with bone marrow lesions in asymptomatic middle-aged women25 and Frey, who showed 
an association between incident HOA and hyperlipidaemia, particularly at younger ages but could not analyse the 
effect of serum lipid profile on HOA as it was modified because of statin exposure26. Our study population was 
similar in age and cardiovascular profile to all three of these earlier studies.
Mechanisms through which lipid metabolism could lead to OA still must be fully elucidated. There is evidence 
that higher HDL-c levels in the synovial fluid have a protective effect27, vascular insults affecting the bone marrow 
next to the cartilage25, and the toxic effect of cholesterol at the joint itself 28 might contribute to the development 
of OA. We were able to detect the protective effect of HDL-c and TG on RHOA as a trend in our population, but 
not an increased risk of RHOA with high TC or LDL-c levels. High HDL-c levels might be present in healthier 
individuals with better physical status and lower prevalence of comorbid conditions29, which could also lead to a 
lower prevalence and incidence of OA. Women in our study were younger and had normal weight to overweight, 
better cardiovascular profile, and no previous cardiovascular disease, compared to other studies7, 11, 17, 18.
Potential limitations of this study should be mentioned. First, the power of the study to show significant effects 
might be limited as we only included 40% of the total eligible population, given the combination of high baseline 
prevalence (45%) of RHOA and the lack of data on cholesterol levels for 15% of the patients. Differences between 
these 277 participants and the rest of the women included must be considered and could limit the generalizability 
Lipid profile
RHOA
Crude OR Age-adjusted OR Fully adjusted OR
HDL-c
Continuous 0.79 (0.44–1.41) 0.74 (0.41–1.34) 0.76 (0.42–1.39)
Categorical
 First quartile (0.72–1.4) 1 1 1
 Second quartile (1.5–1.6) 0.32 (0.16–0.66) 0.34 (0.17–0.71) 0.36 (0.17–0.75)
 Third quartile (1.7–2.0) 0.50 (0.25–0.99) 0.49 (0.24–0.99) 0.52 (0.26–1.06)
 Fourth quartile (2.1–3.4) 0.50 (0.23–1.04) 0.47 (0.22–0.99) 0.48 (0.22–1.03)
TG
Continuous 1.68 (1.11–2.54) 1.50 (0.98–2.29) 1.47 (0.93–2.32)
Categorical
 First quartile (0.40–0.73) 1 1 1
 Second quartile (0.76–1.00) 1.73 (0.92–3.25) 1.54 (0.81–2.93) 1.56 (0.82–2.99)
 Third quartile (1.01–1.40) 1.86 (0.95–3.65) 1.59 (0.79–3.19) 1.57 (0.76–3.22)
 Fourth quartile (1.42–4.9) 2.28 (1.16–4.46) 1.91 (0.95–3.84) 1.83 (0.87–3.86)
TC
Continuous 1.18 (0.98–1.42) 1.10 (0.90–1.34) 1.09 (0.89–1.33)
Categorical
 First quartile (3.1–3.6) 1 1 1
 Second quartile (5.7–6.4) 1.57 (0.84–2.96) 1.46 (0.77–2.77) 1.43 (0.75–2.71)
 Third quartile (6.5–7.4) 1.08 (0.56–2.06) 0.92 (0.47–1.80) 0.91 (0.46–1.80)
 Fourth quartile (7.5–11.2) 2.32 (1.15–4.69) 1.81 (0.86–3.81) 1.75 (0.82–3.70)
LDL-c
Continuous 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
Categorical
 First quartile (1.41–3.40) 1 1 1
 Second quartile (3.42–4.09) 1.33 (0.58–2.18) 1.21 (0.62–2.34) 1.14 (0.58–2.23)
 Third quartile (4.15–5.03) 1.62 (0.83–3.18) 1.35 (0.67–2.71) 1.30 (0.64–2.63)
 Fourth quartile (5.07–7.80) 1.45 (0.72–2.92) 1.18 (0.57–2.44) 1.15 (0.55–2.39)
Table 3. Association between lipid measurements and incident radiographic hand osteoarthritis (RHOA) at 
10 years of follow-up. *Quartiles (limits in mmol/L). Models adjusted for age, body mass index, blood pressure 
medication. **Trend tests (fully adjusted models): HDL-c, high-density lipoprotein cholesterol (p = 0.009); 
TG, triglycerides (p = 0.033); TC, total cholesterol (p = 0.278); LDL-c, low-density lipoprotein cholesterol 
(p = 0.495).
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of our findings. Women included in the study were healthier and younger than those excluded, which might 
partly explain the lack of association between incident RHOA and certain components of the lipid serum profile, 
but also might explain the observed association with other components of serum profile, such as TG and HDL-c 
levels25, 26.
Secondly, serum lipid profile was only measured at Y1, and we were not able to determine if the lipid levels 
detected were previously present or simply reflected an increase at the time of measurement that could be influ-
enced by day-to-day diet and random error. In the same way, changes in lipid serum levels between Y1 and Y11 
were not reported, which prevented us from drawing any conclusion regarding the possible impact of serum lipid 
variations on the outcome or the time lapse between the increase or decrease of these lipids and the outcome. 
Nonetheless, baseline risk factors may be connected in the overall life-course trajectories.
Thirdly, other unmeasured confounders, such as diet, activity of daily living, or socioeconomic status could 
have influenced our results.
Finally, we had no information on lipid-lowering drugs taken by our population at either baseline or dur-
ing follow-up, which could have influenced the nonsignificant association observed between TC and RHOA. 
We would speculate, however, that the proportion of women treated with such therapies was low at the time of 
recruitment, as statins had not yet been launched on the market.
Conclusion
No significant associations between serum lipid profile and RHOA were found after 10 years of follow-up, 
although significant trends were observed in HDL-c and TG associations. Higher HDL-c levels appear to be 
protective and higher TG levels seem to confer a higher risk of RHOA.
Treatments available today for RHOA are mainly focused on the symptomatic relief and functional improve-
ment of the joints affected. The burden of OA is bound to increase due to the lack of effective disease-modifying 
therapies. With this in view, more research is needed to elucidate the aetiology and risk factors of HOA and, spe-
cifically, the mechanisms related to the lipid pathway as well as to the potential effects of lipid-lowering agents on 
the reduction of OA incidence. New pharmacological interventions, especially at early stages, could reduce OA 
incidence and influence the progression of the disease.
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